trending Market Intelligence /marketintelligence/en/news-insights/trending/FERYAO1tBecBsnNXVJ6xRg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Cellectar myeloma drug achieves overall survival of 22.5 months

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Cellectar myeloma drug achieves overall survival of 22.5 months

Cellectar Biosciences Inc.'s lead compound CLR 131 achieved a median overall survival of 22.5 months in patients with multiple myeloma in the first cohort of a phase 1 trial.

The result exceeds past outcomes of marketed treatment modalities for multiple myeloma, Cellectar said in a news release. The overall survival could continue to increase over time as the study is still ongoing.

Meanwhile, patients from the second and third cohort of the trial achieved a median overall survival of 13.2 months and 6.7 months, respectively.

Cellectar Biosciences stocks were up 16.46% to $1.84 as of 9:51 a.m. ET on Aug. 8.